Prognostic nutritional index is an independent prognostic factor for treatment response, survival and drug choice in metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide

Basit Öğe Kaydı
dc.authoridHacioglu, Bekir/0000-0001-8490-3239
dc.authorwosidHacioglu, Bekir/GZH-1824-2022
dc.contributor.authorKucukarda, A.
dc.contributor.authorGokyer, A.
dc.contributor.authorGokmen, I
dc.contributor.authorOzcan, E.
dc.contributor.authorHacioglu, M. B.
dc.contributor.authorErdogan, B.
dc.contributor.authorUzunoglu, S.
dc.date.accessioned2024-06-12T11:12:55Z
dc.date.available2024-06-12T11:12:55Z
dc.date.issued2022
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPurpose: We designed this study to identify the prognostic value of baseline prognostic nutritional index (PNI) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide. Methods: One hundred one mCRPC patients were included. PNI was calculated using formula 10 x serum albumin value (g/dl) + .005 x total lymphocyte count (per mm(3)). ROC analysis was used for determining prognostic PNI value. Results: The statistically significant cut-off value for PNI was 46.62. Initial PSA response and PSA kinetics (early PSA response and 30-50%-90% PSA response at any time) were much better in PNI>46.62 group than the PNI <= 46.62 group (P<.01). In multivariate analysis, baseline PNI level >46.62 was an independent predictor of PSA-PFS (HR: .42; P<.01), radiologic PFS (HR: .53; P<.01), and OS (HR: .42; P<.01). In the PNI <= 46.62 group, median OS was 7.4 months (95% CI: 4.1-10.7) for the abiraterone acetate subgroup vs. 17.6 months (95% CI: 10.1-25.1) for enzalutamide subgroups (P<.01). Conclusion: PNI is a useful, independent prognostic marker for mCRPC patients treated with either abiraterone acetate or enzalutamide. Using pre-treatment PNI may help clinicians in the prediction of survival and decision making based on abiraterone acetate or enzalutamide. (C) 2021 AEU. Published by Elsevier Espana, S.L.U. All rights reserved.en_US
dc.identifier.doi10.1016/j.acuro.2021.04.005
dc.identifier.endpage309en_US
dc.identifier.issn0210-4806
dc.identifier.issn1699-7980
dc.identifier.issue5en_US
dc.identifier.pmid35256324en_US
dc.identifier.startpage301en_US
dc.identifier.urihttps://doi.org/10.1016/j.acuro.2021.04.005
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23364
dc.identifier.volume46en_US
dc.identifier.wosWOS:000835333500006en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoesen_US
dc.publisherElsevier Espanaen_US
dc.relation.ispartofActas Urologicas Espanolasen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPrognostic Nutritional Indexen_US
dc.subjectAbiraterone Acetateen_US
dc.subjectEnzalutamideen_US
dc.subjectCastration-Resistant Prostate Canceren_US
dc.subjectPlus Prednisoneen_US
dc.subjectDouble-Blinden_US
dc.subjectSystemen_US
dc.titlePrognostic nutritional index is an independent prognostic factor for treatment response, survival and drug choice in metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamideen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu